Q-omics provides the consensus-scored RPL19P13 profile across patient tissues and cancer cell-line models. RPL19P13 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, RPL19P13 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, RPL19P13 RNA expression shows 6,141 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CHOL, KIRC, and STAD as cancer lineages where RPL19P13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL19P13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL19P13 survival associations across molecular data types. RPL19P13 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL19P13 RNA expression–survival associations across cancer types. High RPL19P13 expression shows unfavorable associations in CHOL, KIRC, LIHC and MESO, but favorable associations in CESC and LUSC. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify CHOL as the clearest survival context for RPL19P13 RNA expression.
This table summarizes RPL19P13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL19P13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL19P13 shows higher tumor expression in KIRC, HNSC and LUAD. The KIRC box plot shows higher RPL19P13 RNA expression in tumor versus normal tissue (log2 FC = +0.065, t-test p = .011).
This table shows molecular features associated with RPL19P13 in patient tissues and cancer cell lines. In patient samples, RPL19P13 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
